

Dextenza® (dexamethasone ophthalmic insert) – Expanded indication

- On April 7, 2025, the FDA approved Ocular Therapeutix's <u>Dextenza (dexamethasone ophthalmic insert)</u>, for the treatment of:
 - Ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients
 - Ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older.
- This approval expands Dextenza's indications to include pediatric patients.
- The use of Dextenza for the expanded indications is supported by evidence from adequate and
 well-controlled studies in adults with additional safety data from a single active-controlled study in
 pediatric patients aged birth to 5 years old. A similar safety profile was observed between
 pediatric and adult patients.
- Dextenza is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus. A single Dextenza insert releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion.
 - Dextenza is resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert if necessary. Dextenza is intended for single-use only.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.